Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab with carboplatin and paclitaxel for untreated thymic epithelial tumors
2017-004494-13Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab, carboplatin and paclitaxel in thymic carcinoma (TC) and Thymoma type B3 (B3), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: ORR. Started Jun 2021; status: terminated.
02
Drugs
ramucirumabcarboplatinpaclitaxel
03
Conditions
thymic carcinoma (TC)Thymoma type B3 (B3)
Beyond the preview
Go deeper on 2017-004494-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004494-13.